The Alcidion Group Ltd (ASX: ALC) share price has been a positive performer on Tuesday.
In morning trade the healthcare technology company's shares were up 8% to 20.5 cents at one stage.
Why did the Alcidion share price surge higher?
Investors have been buying its shares following the release of a product launch announcement.
According to the release, Alcidion is launching Miya MEMRe, a mobile Electronic Medical Record (EMR).
It allows clinicians to review their current activity and caseload, be notified of critical issues, and access comprehensive patient records on the go.
The app is the first locally developed solution of its kind to offer full access to EMR data. It is also the first mobile EMR solution in Australia using FHIR clinical events.
In addition to this, Miya MEMRe will be the first app that is source system agnostic and uses Artificial Intelligence (AI) to refine critical notifications and action lists.
The release explains that Miya MEMRe is currently being trialled in Australian health services. It is interacting with local clinical systems and providing clinicians in high-intensity areas such as Emergency Departments with critical test results and risk indicators in real-time to enhance decision-making.
Another positive is how it has been designed to exploit the vast amount of information available in an organisation's EMR and clinical systems. This concentrates the data and presents it in an intuitive and focused user interface that aligns to clinical workflow.
This means that clinicians immediately know what's important, can identify problem areas and trends, and access data they need to deliver personalised and precise care.
The company's chief medical officer, Dr Malcolm Pradhan, said: "We believe in the principle of 'safety by default'. By giving clinicians access to the information they need to make decisions and take action, we help them deliver the best possible care and outcomes for their patients."
"At the same time, our technology makes life on the floor simpler, improves efficiency, and can even deliver new insights to help health organisations evolve and innovate. Ultimately, it's about making the delivery of healthcare safer than ever before," he added.
The Miya MEMRe product will be showcased this week at New Zealand's Digital Health Week, South Australia's Supplier Showcase, and the NSW eHealth Expo.
Also rising strongly in the industry on Tuesday are Paradigm Biopharmaceuticals Ltd (ASX: PAR) and Sigma Healthcare Ltd (ASX: SIG) shares. They are up 8% and 4%, respectively, at the time of writing.
